Effects of monoamine oxidase Type B inhibitors on motor and non-motor symptoms in Parkinson's disease: A systematic comparison of rasagiline and selegiline

摘要: During recent decades, clinical research has provided a variety of pharmacological substances that can effectively ameliorate the symptoms Parkinson’s disease (PD), among them selective monoamine oxidase type B inhibitors such as selegiline and rasagiline. Although latter two are nowadays broadly used in practice for monotherapy early PD adjunct therapy to levodopa advanced PD, there is still uncertainty amongst neurologists whether or rasagiline should be preferred antiparkinsonian therapy, since studies directly comparing efficacy both compounds on motor non-motor lacking. This article aims systematically compare effects treatment with fluctuations have been measured previous placebo-controlled, double-blind trials provides an overview about their potential benefits disease. In similar symptomatic classified clinically useful amelioration emerging symptoms. Whereas also demonstrated patients moreover regarded efficacious fluctuations, scientific evidence these indications insufficient. The available data insufficient provide clear picture NMS, but post hoc analyses first positive actions fatigue some aspects attention executive functions non-demented patients.